Drugs / SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351)
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04904549 | May 2021 → Aug 2024 | COVID-19 | Sanofi Pasteur, a Sanofi Company | Terminated | Met primary Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04904549 ↗ |
| Modality | Vaccine | “SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose)” NCT04904549 ↗ |
| Route | Intramuscular | “Route of administration: intramuscular injection.” NCT04904549 ↗ |